This HTML5 document contains 44 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n9http://linked.opendata.cz/resource/drugbank/drug/DB04977/identifier/pubchem-compound/
n10http://linked.opendata.cz/resource/drugbank/drug/DB04977/identifier/pubchem-substance/
n12http://linked.opendata.cz/resource/drugbank/drug/DB04977/identifier/drugbank/
n6http://bio2rdf.org/drugbank:
admshttp://www.w3.org/ns/adms#
n11http://linked.opendata.cz/resource/drugbank/drug/DB04977/identifier/chemspider/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
owlhttp://www.w3.org/2002/07/owl#
n3http://linked.opendata.cz/ontology/drugbank/
n4http://linked.opendata.cz/resource/drugbank/property/
xsdhhttp://www.w3.org/2001/XMLSchema#
n8http://linked.opendata.cz/resource/drugbank/drug/DB04977/identifier/wikipedia/

Statements

Subject Item
n2:DB04977
rdf:type
n3:Drug
n3:description
Aplidine is a compound found in tunicates which shows promise in shrinking tumors in pancreatic, stomach, bladder, and prostate cancers. The specific marine organism is <i>Aplidium albicans</i>. Aplidine consists of peptide molecules. In addition to the cancers mentioned above it is also under consideration as a treatment for some types of leukemia. [Wikipedia]
n3:generalReferences
# Broggini M, Marchini SV, Galliera E, Borsotti P, Taraboletti G, Erba E, Sironi M, Jimeno J, Faircloth GT, Giavazzi R, D'Incalci M: Aplidine, a new anticancer agent of marine origin, inhibits vascular endothelial growth factor (VEGF) secretion and blocks VEGF-VEGFR-1 (flt-1) autocrine loop in human leukemia cells MOLT-4. Leukemia. 2003 Jan;17(1):52-9. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/12529660 # Depenbrock H, Peter R, Faircloth GT, Manzanares I, Jimeno J, Hanauske AR: In vitro activity of aplidine, a new marine-derived anti-cancer compound, on freshly explanted clonogenic human tumour cells and haematopoietic precursor cells. Br J Cancer. 1998 Sep;78(6):739-44. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/9743292 # Sparidans RW, Kettenes-van den Bosch JJ, van Tellingen O, Nuyen B, Henrar RE, Jimeno JM, Faircloth G, Floriano P, Rinehart KL, Beijnen JH: Bioanalysis of aplidine, a new marine antitumoral depsipeptide, in plasma by high-performance liquid chromatography after derivatization with trans-4-hydrazino-2-stilbazole. J Chromatogr B Biomed Sci Appl. 1999 Jun 11;729(1-2):43-53. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/10410926 # Celli N, Gallardo AM, Rossi C, Zucchetti M, D'Incalci M, Rotilio D: Analysis of aplidine (dehydrodidemnin B), a new marine-derived depsipeptide, in rat biological fluids by liquid chromatography-tandem mass spectrometry. J Chromatogr B Biomed Sci Appl. 1999 Aug 20;731(2):335-43. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/10510788 # Nuijen B, Bouma M, Henrar RE, Floriano P, Jimeno JM, Talsma H, Kettenes-van den Bosch JJ, Heck AJ, Bult A, Beijnen JH: Pharmaceutical development of a parenteral lyophilized formulation of the novel antitumor agent aplidine. PDA J Pharm Sci Technol. 2000 May-Jun;54(3):193-208. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/10927911 # Brandon EF, Sparidans RW, van Ooijen RD, Meijerman I, Lazaro LL, Manzanares I, Beijnen JH, Schellens JH: In vitro characterization of the human biotransformation pathways of aplidine, a novel marine anti-cancer drug. Invest New Drugs. 2007 Feb;25(1):9-19. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/16633717
n3:group
investigational
n3:indication
Intended for the treatment of various forms of cancer.
owl:sameAs
n6:DB04977
dcterms:title
Aplidine
adms:identifier
n8:Aplidine n9:5459174 n10:8142211 n11:4573001 n12:DB04977
n3:mechanismOfAction
Aplidine inhibits the growth and induces apoptosis in MOLT-4 cells through the indirect inhibition of VEGF secretion which blocks the VEGF/VEGFR-1 autocrine loop necessary for the growth of these cells.
n3:synonym
DDB Dehydrodidemnin B
n3:IUPAC-Name
n4:271B61C3-363D-11E5-9242-09173F13E4C5
n3:InChI
n4:271B61C9-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n4:271B61C8-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n4:271B61C5-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n4:271B61C6-363D-11E5-9242-09173F13E4C5
n3:SMILES
n4:271B61C7-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n4:271B61C1-363D-11E5-9242-09173F13E4C5
n3:logP
n4:271B61BF-363D-11E5-9242-09173F13E4C5 n4:271B61C2-363D-11E5-9242-09173F13E4C5
n3:logS
n4:271B61C0-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Acceptor-Count
n4:271B61CF-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n4:271B61D0-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n4:271B61CA-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n4:271B61CB-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n4:271B61CD-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n4:271B61CC-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n4:271B61CE-363D-11E5-9242-09173F13E4C5
n3:affectedOrganism
Humans and other mammals
n3:casRegistryNumber
137219-37-5
n3:category
n3:Bioavailability
n4:271B61D5-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n4:271B61D7-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n4:271B61D8-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n4:271B61D4-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n4:271B61D3-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n4:271B61D6-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n4:271B61C4-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n4:271B61D1-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n4:271B61D2-363D-11E5-9242-09173F13E4C5